References
- Kübler W, Haass M. Cardioprotection: definition, classification, and fundamental principles. Heart. 1996;75:330–333.
- Simko F, Simko J. Heart failure and angiotensin converting enzyme inhibition: problems and perspectives. Physiol Res. 1999;48:1–8.
- Simko F, Simko J, Fabryova M. ACE-inhibition and angiotensin II receptor blockers in chronic heart failure: pathophysiological consideration of the unresolved battle. Cardiovasc Drugs Ther. 2003;17:287–290.
- Pitt B, Remme W, Zannad F, et al. Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators 2003 eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321.
- Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–1158.
- Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. Jama. 2001;285:1711–1718.
- Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975.
- Simko F. Statins – a perspective for left ventricular hypertrophy treatment (review). Eur J Clin Invest. 2007;37:681–691.
- Palatini P, Rosei EA, Casiglia E, et al. Management of the hypertensive patient with elevated heart rate: statement of the second consensus conference endorsed by the European Society of Hypertension. J Hypertens. 2016;34:813–821.
- Simko F, Baka T, Paulis L, et al. Elevated heart rate and nondipping heart rate as potential targets for melatonin: a review. J Pineal Res. 2016;61:127–137.
- Amsallem E, Kasparian C, Haddour G, et al. Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst Rev. 2005;1:CD002230.
- Campo G, Pavasini R, Morciano G, et al. Data on administration of cyclosporine, nicorandil metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention. Data Brief. 2017;14:197–205.
- Reiter RJ, Mayo JC, Tan DX, et al. Melatonin as an antioxidant: under promises but over delivers. antioxidant: under promises but over delivers. J Pineal Res. 2016;61:253–278.
- Simko F, Paulis L. Melatonin as a potential antihypertensive treatment. J Pineal Res. 2007;42:319–322.
- Simko F, Pechanova O. Remodelling of the heart and vessels in experimental hypertension: advances in protection. J Hypertens. 2010;28(Suppl 1):S1–S6.
- Simko F, Paulis L. Antifibrotic effect of melatonin – perspective protection in hypertensive heart disease. Int J Cardiol. 2013;168:2876–2877.
- Saha SP, Whayne TF Jr. Coenzyme Q10 in human health: supporting evidence? South Med J. 2016;109:17–21.
- Adamcova M, Popelova-Lencova O, Jirkovsky E, et al. Cardiac troponins: translational biomarkers in cardiology: theory and practice of cardiac troponin high-sensitivity assays. Biofactors. 2016;42:133–148.
- Adamcova M, Ruzickova S, Simko F. Multiplexed immunoassays for simultaneous quantification of cardiovascular biomarkers in the model of H(G)-nitro-L-arginine methylester (L-NAME) hypertensive rat. J Physiol Pharmacol. 2013;64:211–217.
- Heusch G. Critical issues for the translation of cardioprotection. Circ Res. 2017;120:1477–1486.
- Chamuleau SAJ, van der Naald M, Climent AM, et al.; Transnational Alliance for Regenerative Therapies in Cardiovascular Syndromes (TACTICS) Group. Translational research in cardiovascular repair: a call for a paradigm shift. Circ Res. 2018;122:310–318.
- Packer M. The impossible task of developing a new treatment for heart failure. J Card Fail. 2002;8:193–196.